News from sutrovax A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 04, 2020, 08:00 ET SutroVax Appoints Andrew Guggenhime as Chief Financial Officer and Chief Business Officer

SutroVax, a biopharmaceutical company dedicated to the development of superior and novel vaccines designed to prevent or treat some of the most...


Mar 26, 2020, 07:00 ET SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

SutroVax, a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common...


Jan 30, 2020, 08:00 ET SutroVax Announces Executive Appointment

SutroVax, a biopharmaceutical company dedicated to developing best-in-class conjugate vaccines and novel complex antigen-based vaccines designed to...


Sep 03, 2019, 08:00 ET SutroVax Receives CARB-X Award for Up to $15 Million to Develop a Universal Vaccine to Prevent Group A Streptococcus Infections

SutroVax, Inc., a biopharmaceutical company dedicated to the development of best-in-class conjugate vaccines and novel complex antigen-based vaccines ...


Feb 25, 2019, 08:00 ET SutroVax Announces Publication of Preclinical Proof of Concept for Preventive Vaccine for Periodontal Disease

SutroVax Inc., a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to...


Jan 14, 2019, 08:00 ET SutroVax Announces Executive Appointments

SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to...


Jun 07, 2018, 08:04 ET SutroVax Announces $85M Series C Financing led by TPG Growth

SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to...


Oct 11, 2017, 08:00 ET SutroVax Appoints Veteran Vaccine Experts to Executive Team

SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to...


Jul 19, 2017, 08:00 ET Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of Directors

SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to...


Mar 21, 2017, 07:00 ET SutroVax Announces Closing of $64M via Series B Financing

SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to...


Jan 04, 2017, 08:00 ET SutroVax Announces Appointment of Industry Leaders to Executive Team, Board & SAB

SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to...


May 03, 2016, 08:00 ET SutroVax Announces Appointment of Paul Sauer as Vice President, Process Development & Manufacturing

SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to...


Jan 06, 2016, 08:55 ET SutroVax Announces Appointment of Distinguished Conjugate Vaccine Developer Dr. Bruce Forrest to Scientific Advisory Board

SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to...


Jul 24, 2015, 06:57 ET SutroVax lève 22 millions de dollars en financement de série A

SutroVax, une société biopharmaceutique de vaccins récemment créée, a annoncé aujourd'hui le bouclage d'un financement de série A d'un montant de 22...


Jul 23, 2015, 08:00 ET SutroVax raises $22 million in Series A

SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is...


Jul 23, 2015, 04:43 ET SutroVax erzielt 22 Millionen US-Dollar in Serie-A-Finanzierung

SutroVax, ein kürzlich gegründetes Biopharma-Unternehmen für Impfstoffe, hat heute den Abschluss einer Finanzierungsrunde der Serie A über 22...